Sodium-potassium-chloride cotransporter 2 (NKCC2) (NKCC2)

Sodium-potassium-chloride cotransporter 2 (NKCC2), encoded by the SLC12A1 gene, is a critical membrane transport protein located on the apical surface of the thick ascending limb of Henle in the kidney [2, 4]. It mediates the electroneutral symport of one sodium, one potassium, and two chloride ions from the tubular lumen into the renal epithelial cells, accounting for approximately 20-25% of total filtered sodium reabsorption [3, 12]. This transport process is essential for establishing the medullary osmotic gradient required for urine concentration and for the regulation of systemic blood pressure and fluid volume [5, 6]. Mutations in the SLC12A1 gene cause Bartter syndrome type 1, a severe salt-wasting disorder characterized by hypotension, hypokalemia, and metabolic alkalosis [1, 13]. NKCC2 is the primary molecular target of loop diuretics, such as furosemide and bumetanide, which are widely prescribed to manage edema in heart failure, cirrhosis, and renal disease, as well as to treat hypertension [8, 10]. While highly effective, pharmacological inhibition of NKCC2 can lead to significant electrolyte imbalances, including hypokalemia and hypomagnesemia, and potential ototoxicity due to cross-reactivity with the NKCC1 isoform in the inner ear [1, 11].

Other names

SLC12A1Bumetanide-sensitive cotransporter 1BSC1BSC-1Solute carrier family 12 member 1Na-K-2Cl cotransporter 2

Inhibition of the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of Henle's loop, which prevents the reabsorption of sodium, potassium, and chloride ions, leading to increased diuresis and natriuresis.